Experimental dermatology and cutaneous biology
2023 Activity indicators
- 6 public competitive projects: MICINN-MINECO, CAM-UAM, ISCIII, CAM
- 10 private led projects
- 35 clinical led trials
- 48 publications
- IF: 213.56
- Q1 publications: 27 (56%)
- D1 publications: 8 (17%)
- 4 thesis
- 4 awards
- Translation: 2nd TricoHRC Trichology Practical Handbook and a consensus document (PMID: 37477225)
- 2 actions with an impact on society: 11th edition of the Trichology Refresher Course, The Psoriasis revolution event 2023
- National public agency evaluators: 2 researchers
- Members of editorial committees: 2 researchers
- 4 months stay in foreign institutions:
- Showa Pharmaceutical University (Machida, Tokyo, Japan)
- 4 visitors hosted and 20 months of stay:
- Universidad Politécnica de Madrid (UPM)
Milestones
-
Dr. Sergio Vañó-Galván has been recognised with the honorary award to one of the most reputable doctors in Spain by MERCO and ODS.
-
Dr. Álvaro González-Cantero has received competitive funding from the National Plan grants (AES 2022, ISCIII) for the project 'Subclinical atherosclerosis in patients with psoriasis: search for new molecular biomarkers' Ref. PI22/01847.
-
Award of a pre-doctoral health research training contract (PFIS), AES 2023/ISCIII, under the supervision of Dr. Pedro Jaén, Dr. Álvaro González-Cantero and Dr. Óscar Muñoz-Moreno Arrones.
-
Intramural funding from the FIBioHRC for the development of the project 'Immunological characterisation of drug-induced and idiopathic bullous pemphigoid'. PI: Dr. Montserrat Fernández Guarino.
-
The clinical research group is characterised by its constancy and productivity. It maintains a considerable number of clinical trials in various dermatological pathologies, and continues to publish articles in first quartile and first decile journals in the speciality, such as two publications in the prestigious Journal of the American Academy of Dermatology (10.1016/j.jaad.2023.02.048 and 10.1016/j.jaad.2020.12.090).
Bibliometrics
Articles | Accum. IF | Mean IF | Articles Q1 or Q2 | % in Q1 or Q2 | Articles D1 | % in D1 | |
---|---|---|---|---|---|---|---|
2019 | 52 | 130.32 | 2.51 | 20 | 38 | 11 | 21 |
2020 | 59 | 296.17 | 6.04 | 42 | 71 | 24 | 41 |
2021 | 44 | 284.95 | 8.38 | 29 | 66 | 16 | 36 |
2022 | 37 | 182.59 | 6.30 | 20 | 54 | 7 | 19 |
2023 | 48 | 213.56 | 5.48 | 37 | 77 | 8 | 17 |
240 | 1107.60 | 5.74 | 148 | 61 | 66 | 27 |
* Only original articles, editorials, guidelines and reviews.